Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is a high-growth, direct-to-patient healthcare company that offers convenient and cost-effective virtual medical care and pharmacy services. With a strong portfolio of brands, including a nationwide pharmacy network, a wholly-owned commercial pharmacy, and a fully integrated patient care center, the company is well-positioned to capitalize on the growing demand for telehealth and digital health services. Its recent collaboration with Novo Nordisk to offer FDA-approved weight loss treatments further showcases its commitment to providing high-quality healthcare options. While the industry is competitive and subject to uncertainties such as the impact of COVID-19, the company's strong financials, with a projected EV/Revenue multiple of 2.3x, and strategic partnerships make it a promising investment opportunity.

Bears say

LifeMD is facing significant headwinds due to lower-cost competitors in the weight management sector and the transition to branded GLP-1s has created revenue lumpiness. Additionally, the company's current cash position and negative cash flow from operating activities may not be sufficient for future operations, and there are various risks associated with being a young, high-growth company in the healthtech space. These factors lead to a negative outlook on LifeMD's stock.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.